Survey Study for Velaglucerase Alfa (VPRIV) in Japan

Takeda logo

Takeda

Status

Completed

Conditions

Gaucher Disease

Study type

Observational

Funder types

Industry

Identifiers

NCT03625882
SHP-GCB-401

Details and patient eligibility

About

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Enrollment

77 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female participants with a confirmed diagnosis of Gaucher disease
  • Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease
  • Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period

Exclusion criteria

-

Trial design

77 participants in 1 patient group

Gaucher Disease Participants Treated With VPRIV
Description:
Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.

Trial contacts and locations

35

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems